Escitalopram, agomelatine, and duloxetine led sustained depression response across the review
A new systematic review in The Lancet Psychiatry places three antidepressants ahead of fluoxetine for long-term symptom relief: escitalopram, agomelatine, and duloxetine. The analysis compared 20 drugs used for depression and found these three were associated with the highest rates of sustained response, a clinically important outcome when treatment extends beyond the first few weeks and the goal shifts from short-term symptom reduction to durable remission.
The review drew on 115 randomized controlled trials and included data from more than 30,000 participants. Among the drugs studied, escitalopram had the strongest signal, with 62% higher odds of lasting symptom relief than fluoxetine. Duloxetine followed with 57% higher odds, while agomelatine showed 40% higher odds of sustained improvement. Those numbers do not mean every patient will do better on those medications, but they do give clinicians a stronger evidence base when planning treatment beyond the acute phase.
Fluoxetine has long been a familiar reference drug in depression care, partly because it was one of the first selective serotonin reuptake inhibitors to enter widespread use. Its longevity makes it a useful benchmark, not a guarantee of superiority. In practical terms, the comparison suggests that some antidepressants may hold their effect more reliably over time, which matters in a condition where relapse, residual symptoms, and medication discontinuation all remain common bedside problems.
Why one antidepressant may hold up better over months than another
Long-term depression treatment is not just about whether a drug lifts mood early. It is about whether the benefit persists when life stressors, side effects, adherence problems, and medical comorbidities begin to shape the course of care. Depression is biologically heterogeneous, and antidepressants differ in receptor activity, tolerability, metabolism, and the kinds of symptoms they may relieve most effectively. Those differences help explain why a medication with strong short-term efficacy may not always be the best choice for sustained control.
Escitalopram sits in the SSRI class and is often favored in clinical practice because of its comparatively low potential for drug-drug interactions. That can matter for patients already taking multiple medications, where avoiding pharmacokinetic conflict becomes part of preserving adherence and minimizing adverse events. Duloxetine operates differently, acting on both serotonin and norepinephrine. Its dual mechanism can be useful when depression overlaps with chronic pain, a combination frequently seen in routine practice and one that can intensify functional impairment if untreated.
Agomelatine is the most distinctive of the three, acting on serotonin and melatonin pathways. The circadian angle is clinically plausible because sleep-wake disruption is woven into depression for many patients. A medication that better supports sleep timing may ease symptom burden in people whose mood disorder is tightly linked to insomnia or disturbed circadian rhythm. The same mechanism, however, comes with a safety caveat: liver toxicity concerns have limited its use in the United States.
The data do not erase the fact that depression treatment remains highly individualized.
Why the United States may favor escitalopram and duloxetine over agomelatine
Agomelatine is not approved by the Food and Drug Administration, so its role in the United States is essentially theoretical for routine prescribing. In contrast, escitalopram and duloxetine are available and already integrated into everyday practice. For U.S. clinicians, the review may sharpen attention on those two agents when long-term maintenance is the central question and no contraindications are present.
Even there, the choice is not automatic. Duloxetine is not suitable for people with severely impaired kidney function, and escitalopram requires caution in patients with a history of QT prolongation or in those taking other medications that can lengthen cardiac repolarization. Agomelatine carries the possibility of serious liver injury and is therefore a poor fit for patients with liver disease or higher hepatic risk. These are not abstract caveats; they determine whether a medication can be used safely at all.
There is also the broader psychiatric issue of mood switching. Any antidepressant can unmask mania or shift the diagnosis toward bipolar disorder in a vulnerable patient. That possibility forces clinicians to review personal and family history carefully before starting treatment, especially when depressive symptoms include agitation, decreased need for sleep, or a prior pattern of antidepressant-induced activation. The drug may be only part of the decision; the diagnosis itself can change the treatment plan.
A single-sentence headline about “the best antidepressant” would miss the core clinical point. These findings refine the conversation, but they do not replace it.
What the comparison against fluoxetine really changes at the bedside
Using fluoxetine as the comparator gives the review a recognizable anchor. Fluoxetine remains an effective antidepressant and should not be abandoned if a patient is doing well on it. The stronger message is narrower: among the 20 drugs evaluated, several alternatives showed more favorable sustained response signals, and that matters when a patient is only partially improved or keeps relapsing after initial benefit.
Perry Anthony Maliuanag, MD, FAPA, framed the practical side of the finding by noting that escitalopram is often attractive in patients with multiple comorbidities because of fewer interaction concerns, while duloxetine can be especially useful when chronic pain travels with depression. He also pointed to agomelatine’s circadian mechanism as a possible fit for patients whose depressive symptoms are tied to sleep-wake disruption, even though liver safety has prevented U.S. approval.
For patients, the immediate consequence is not a one-size-fits-all ranking of antidepressants. It is a more informed discussion with a clinician about symptom profile, medical comorbidity, prior response, family history, concomitant medications, and the risks attached to each agent. For prescribers, the review adds weight to a medication choice that already depends on the balance between efficacy and safety over months rather than days.
The unresolved issue is not whether one drug can outperform another in a pooled analysis. It is how well those advantages hold up in a specific patient with insomnia, pain, kidney disease, liver risk, cardiac conduction issues, or a possible bipolar spectrum disorder.